Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5136455 | 0.88 | LMNA (0.54) | ALDH1A1GAAPKMLMNACYP2D6 | |
| Glycine SCHEMBL6374478 | 0.86 | LMNA (0.50) | ALDH1A1GAAPKMLMNACYP2D6 | |
| SCHEMBL25204350 | 0.85 | ALDH1A1 (0.47) | ALDH1A1GAAPKMLMNACYP2D6 | |
| SCHEMBL21814438 | 0.84 | LMNA (0.59) | ALDH1A1GAALMNAMAPK1MAPT | |
| SCHEMBL21814649 | 0.84 | LMNA (0.59) | ALDH1A1GAALMNAMAPK1MAPT | |
| SCHEMBL7140779 | 0.83 | LMNA (0.47) | ALDH1A1GAAPKMLMNACYP2D6 | |
| SCHEMBL20489941 | 0.82 | CA1 (0.51) | ALDH1A1GAAPKMLMNACYP2D6 | |
| SCHEMBL18281078 | 0.81 | LMNA (0.68) | ALDH1A1GAALMNACYP2D6MAPK1 | |
| SCHEMBL717926 | 0.81 | LMNA (0.68) | ALDH1A1GAALMNACYP2D6MAPK1 | |
| SCHEMBL15517281 | 0.81 | CA1 (0.54) | ALDH1A1GAALMNAMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261918-A1 | Silicon Compounds and Their Use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-23 | — | — | US | disclosed |
| EP-1824863-B1 | SILICON COMPOUNDS AND THEIR USE | TAKEDA CAMBRIDGE LTD (GB) | 2008-10-08 | — | — | EP | disclosed |
| EP-1824863-A1 | SILICON COMPOUNDS AND THEIR USE | Takeda Cambridge Limited (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006064277-A1 | SILICON COMPOUNDS AND THEIR USE | TAKEDA CAMBRIDGE LIMITED (GB) | 2006-06-22 | — | — | WO | disclosed |
| EP-0672678-B1 | Azapeptide derivative | FUJIREBIO KK (JP) | 2000-10-25 | — | — | EP | disclosed |
| US-5965538-A | FOR TREATING NERVOUS INFLAMMATION OF RESPIRATORY SYSTEMS, ASTHMA, BRONCHOSPASM | FUJIREBIO INC. (JP) | 1999-10-12 | — | — | US | disclosed |
| US-5837687-A | BRONCHODILATORS, ANTIHISTAMINES AND ANTIINFLAMMATORY AGENTS; ASTHMA; ANTAGONIST OF NEUROKININ RECEPTORS | FUJIREBIO INC. (JP) | 1998-11-17 | — | — | US | disclosed |
| EP-0672678-A1 | Azapeptide derivative | FUJIREBIO Inc. (JP) | 1995-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261918-A1 | Silicon Compounds and Their Use | SOST, SIK2, SCLY | ALDH1A1 2254/4885GAA 139/4885PKM 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.